Existing Regulus Agreements Sample Clauses

Existing Regulus Agreements. AstraZeneca acknowledges that certain of the Regulus Technology is in-licensed, or was otherwise acquired by Regulus, from Third Parties under the Existing Regulus Agreements, and that Regulus is obligated to pay royalties, milestones and other payments to the Licensor(s) under such Existing Regulus Agreements as a result of the development or commercialization of Products by AstraZeneca or any of its Affiliates or sublicensees to the extent that such Products are covered by the applicable Patents or Know-How licensed to Regulus under such Existing Regulus Agreement. All such royalties, milestones and other payments under such Existing Regulus Agreements shall be paid by Regulus and AstraZeneca shall under no circumstances whatsoever be liable for any such royalties, milestones or other payments.
Sample 1Sample 2
AutoNDA by SimpleDocs
Existing Regulus Agreements. Sanofi acknowledges that certain of the Regulus Technology Controlled by Regulus as of the Effective Date were in-licensed, or otherwise acquired by Regulus, from Third Parties under the Existing Regulus Agreements, and that Regulus is obligated to pay In-License Royalties and/or In-License Milestones to the Licensor(s) under such Existing Regulus Agreements as a result of the Development or Commercialization of Products by Sanofi or any of its Affiliates or sublicensees to the extent that such Products are covered by the applicable Third Party Patents. The Parties acknowledge and agree that Regulus will be responsible for paying […***…]% of the In-License Royalties, In-License Milestones and Other In-License Payments that become due to the Licensor(s) under the Existing Regulus Agreements.
Sample 1
Existing Regulus Agreements. This Appendix 5 contains a list of certain agreements in effect as of the Effective Date between Regulus and certain Third Parties that may, as applicable, place certain encumbrances or limitations on the licenses or sublicenses granted to Sanofi, the exclusivity covenants, and the representations and warranties, where specified in the Agreement. As set forth in the Agreement, the information and disclosures contained in this Appendix 5 are intended only to qualify and limit the licenses granted by Regulus to Sanofi, the exclusivity covenants, and the representations and warranties given by Regulus under the Agreement and do not expand in any way the scope or effect of any such licenses, representations or warranties. Nothing herein constitutes an admission of any liability or obligation of Regulus nor an admission against any interest of Regulus. The inclusion of this Appendix 5 or the information contained in this Appendix 5 does not indicate that Regulus has determined that this Appendix 5 or the information contained in this Appendix 5, when considered individually or in the aggregate, is necessarily material to Regulus. Existing Regulus Agreements […***…] […***…] […***…] […***…] […***…] […***…] * Note: these agreements are not applicable on the Effective Date, and would only apply if Sanofi designates a Collaboration Target under Section 3.6 that is covered by the Patents in-licensed by Regulus under such agreements. ***Confidential Treatment Requested APPENDIX 6
Sample 1
Existing Regulus Agreements. (a) Notwithstanding Section 6.10.1 of the Agreement to the contrary, from and after the First Amendment Date, Sanofi shall be responsible for paying 100% of the In-License Royalties, In-License Milestones and Other In-License Payments that become due to the Licensor(s) under the Existing Regulus Agreements (the “Existing Third Party Licensors”) as a result of the Development or Commercialization of Mir-21 Products by Sanofi or any of its Affiliates or sublicensees to the extent that such Mir-21 Products are covered by the applicable Third Party Patents, regardless of whether any such Existing Regulus Agreement is assigned to Sanofi pursuant to Paragraph 5.4 of this First Amendment or Sanofi enters into a Stand-by License Agreement with the applicable Existing Third Party Licensor. With respect to each Existing Regulus Agreement that is assigned to Sanofi pursuant to Paragraph 5.4 of this First Amendment or with respect to which Sanofi enters into a Stand-by License Agreement with the applicable Existing Third Party Licensor, Sanofi shall be solely and directly responsible and liable to the applicable Existing Third Party Licensor for payment of, and will pay directly to such applicable Existing Third Party Licensor, all such In-License Royalties, In-License ***Confidential Treatment Requested 11 Milestones and Other In-License Payments that become due to such Existing Third Party Licensor under such Existing Regulus Agreement as a result of the Development or Commercialization of Mir-21 Products by Sanofi or any of its Affiliates or sublicensees. With respect to each Existing Regulus Agreement that neither is assigned to Sanofi pursuant to Paragraph 5.4 of this First Amendment nor is the subject of a Stand-by License Agreement entered into by Sanofi with the applicable Existing Third Party Licensor, Sanofi shall: (i) notify Regulus in writing of the achievement of any milestone event listed on Schedule 10.2(j), by a Mir-21 Product with respect to which an In-License Milestone is due under such Existing Regulus Agreement within […***…] days after the achievement thereof; (ii) deliver to Regulus at least […***…] days before the end of each Calendar Quarter Sanofi’s good faith forecast of Net Sales (as defined in such Existing Regulus Agreement) of Mir-21 Products that are subject to In-License Royalty payment obligations under such Existing Regulus Agreement and the amount of In-License Royalties that would be due with respect to such estimated Net Sales; (i...
Sample 1
Existing Regulus Agreements. […***…] Agreement among Regulus and […***…] dated […***…]. […***…] Agreement among […***…] and Regulus dated […***…]. […***…] Agreement between […***…] and Regulus dated […***…]. […***…] Agreement between […***…] and Regulus dated […***…]. ***Confidential Treatment Requested Appendix 4 […***…] […***…] ***Confidential Treatment Requested Appendix 5 Invoices to AstraZeneca All invoices to be sent to AstraZeneca AB, AstraZeneca R&D Mölndal, Finance Accounting, X-000 00, Xxxxxxxxx, Xxxxxx. • Invoice date (date of issue) • Invoice number • Purchase Order number: ___________ If not yet available, then state (to be provided) • Regulus’ Tax ID number • Complete reference for the Agreement: Insert the following information: Name of AstraZeneca point of contact e.g. Science Lead(s) / Alliance manager/JSC member cost center (to be provided by AZ) Dealz ID (to be provided by AZ) • Full address of Regulus • Description and quantity of goods or services (e.g., Signing Payment, Quarter 2 Payment, etc.) • Delivery date, if different from invoice date • Invoice amount and currency in U.S. Dollars • Bank details, including, if necessary, IBAN code, account number and bank code and/or SWIFT address.
Sample 1
Existing Regulus Agreements. This Appendix 5 contains a list of certain agreements in effect as of the Effective Date between Regulus and certain Third Parties that may, as applicable, place certain encumbrances or limitations on the licenses or sublicenses granted to Sanofi, the exclusivity covenants, and the representations and warranties, where specified in the Agreement. As set forth in the Agreement, the information and disclosures contained in this Appendix 5 are intended only to qualify and limit the licenses granted by Regulus to Sanofi, the exclusivity covenants, and the representations and warranties given by Regulus under the Agreement and do not expand in any way the scope or effect of any such licenses, representations or warranties. Nothing herein constitutes an admission of any liability or obligation of Regulus nor an admission against any interest of Regulus. The inclusion of this Appendix 5 or the information contained in this Appendix 5 does not indicate that Regulus has determined that this Appendix 5 or the information contained in this Appendix 5, when considered individually or in the aggregate, is necessarily material to Regulus. Existing Regulus Agreements […***...] ***Confidential Treatment Requested APPENDIX 6 POC PROGRAM PLANS Overview There are two main projects being prosecuted within the ongoing collaboration between Sanofi and Regulus Therapeutics, miR-21 and miR-221. Within the miR-21 project there are two therapeutic areas being evaluated. The first area is focused on renal fibrosis, specifically a human condition known as Alport Syndrome. The second therapeutic area of interest is Oncology. For the miR-221 project the sole therapeutic area of interest in Oncology. This document will frame the ongoing activities and the planned activities within these collaborations with a more detailed overview of the miR-21 fibrosis program given that this is […***…]. The miR-21 and miR-221 Oncology projects are focused on […***…] and the […***…]. The initial POC Program Plans for the miR-21 fibrosis program, the miR-21 oncology program and the miR-221/222 oncology program are attached hereto as Xxxxxxxx 0X, Xxxxxxxx 0X xxx Xxxxxxxx 0X, respectively. ***Confidential Treatment Requested APPENDIX 6A INITIAL MIR-21 FIBROSIS POC PROGRAM PLAN miR-21 Fibrosis focusing on Alport Syndrome […***…] has been […***…] within the miR-21 fibrosis program. In non GLP toxicology experiments […***…]. The […***…] by comparing the […***…] required for efficacy with the […***…] that is ...
Sample 1

Related to Existing Regulus Agreements

  • Previous Agreements This Agreement constitutes the entire understanding of the parties and is intended as a final expression of their agreement and a complete statement of the terms thereof. There are no promises, terms, conditions, or obligations, other than contained herein. This Agreement shall supersede all previous communications, representations, or agreements, either oral or written, between the parties.

  • Existing Agreements The Executive represents to the Company that he is not subject or a party to any employment or consulting agreement, non-competition covenant or other agreement, covenant or understanding which might prohibit him from executing this Agreement or limit his ability to fulfill his responsibilities hereunder.

  • Supersedes Previous Agreements This Agreement supersedes all prior or contemporaneous negotiations, commitments, agreements and writings with respect to the subject matter hereof, all such other negotiations, commitments, agreements and writings will have no further force or effect, and the parties to any such other negotiation, commitment, agreement or writing will have no further rights or obligations thereunder.

  • Letter Agreements The Company shall not take any action or omit to take any action which would cause a breach of any of the Letter Agreements executed and will not allow any amendments to, or waivers of, such Letter Agreements without the prior written consent of the Representative.

  • Previous Agreement By execution of this Agreement, any prior agreement between the Company, Underwriter and the Broker or between Company and the signing principal(s) related specifically to the business transacted under this Agreement is terminated as of the effective date of this Agreement; but while this Agreement remains in force, any rights of Broker to receive compensation under the terms and conditions of the prior agreement are continued hereunder, and such earned compensation shall be payable at the rate, for the remainder of the period, and on the basis applicable as if that agreement remained in force.

  • Parties to Lock-Up Agreements The Company has furnished to the Underwriters a letter agreement in the form attached hereto as Exhibit A (the “Lock-up Agreement”) from each of the persons listed on Exhibit B. Such Exhibit B lists under an appropriate caption the directors and executive officers of the Company. If any additional persons shall become directors or executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.

  • Prior Agreements; Amendments This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. This Agreement may be amended only by a written instrument duly executed by the parties hereto or their respective successors or assigns.

Time is Money Join Law Insider Premium to draft better contracts faster.